STOCK TITAN

Can-Fite BioPharma Ltd. - CANF STOCK NEWS

Welcome to our dedicated page for Can-Fite BioPharma Ltd. news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. stock.

Can-Fite BioPharma Ltd. (CANF) is a clinical-stage biopharmaceutical innovator advancing oral therapies for cancer, liver diseases, and inflammatory conditions through its proprietary A3 adenosine receptor (A3AR) platform. This page serves as your definitive source for official company announcements, clinical trial updates, and strategic developments.

Investors and industry professionals will find curated press releases detailing progress across Can-Fite’s pipeline, including Phase II/III trials for Piclidenoson in psoriasis and Namodenoson’s dual applications in liver cancer and NASH. All content is verified through primary sources to ensure accuracy and timeliness.

Key updates cover regulatory milestones, partnership announcements, and peer-reviewed research findings. The collection emphasizes developments in targeted small molecule therapeutics while maintaining accessibility for both specialist and general audiences.

Bookmark this page to efficiently monitor Can-Fite’s advancements in addressing multi-billion dollar medical markets through its differentiated A3AR approach. Check regularly for critical updates that may influence market positioning and therapeutic innovation.

Rhea-AI Summary

Can-Fite BioPharma Ltd. (NYSE American: CANF) reported its financial results for Q1 2022, with revenues of $0.20 million, up 38.5% from $0.15 million in Q1 2021. The company holds $16.5 million in cash and equivalents. R&D expenses rose 39.8% to $1.82 million due to ongoing clinical trials for psoriasis and NASH treatments. The net loss increased to $2.43 million from $1.87 million year-on-year. Upcoming milestones include Phase III psoriasis study results expected in Q2 2022 and ongoing Phase IIb and III studies for NASH and liver cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
-
Rhea-AI Summary

Can-Fite BioPharma Ltd. (NYSE American: CANF) has received a patent for its A3 Adenosine Receptor ligand aimed at treating ectopic fat accumulation, particularly in non-alcoholic steatohepatitis (NASH) and fatty liver disease. The patent is recognized in about 40 countries, including Japan and the EU. The market for NASH treatment is expected to reach $35 billion by 2025. Can-Fite is currently conducting a Phase IIb clinical trial for its drug candidate Namodenoson, which previously met key endpoints in Phase IIa trials, showing safety and efficacy in reducing liver fat.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
none
-
Rhea-AI Summary

Can-Fite BioPharma (NYSE American: CANF) announced a Phase II study where Namodenoson, an oral drug targeting liver cancer, cleared all lesions in an advanced patient. The pivotal Phase III trial has received FDA and EMA approval and is now open to recruit around 450 hepatocellular carcinoma patients. The drug selectively binds to the A3 adenosine receptor, prevalent in cancer cells. CEO Dr. Pnina Fishman is set to present at the Adenosine Pathway Targeted Cancer Immunotherapy Summit in Boston on May 12, 2022, highlighting the drug's promising results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.3%
Tags
conferences
Rhea-AI Summary

Can-Fite BioPharma (NYSE American: CANF) is advancing a topical treatment for psoriasis using its Phase III oral drug candidate, Piclidenoson. Recent preclinical studies show significant efficacy in managing psoriasis symptoms. The global psoriasis drug market, valued at $11.37 billion, is projected to grow at a CAGR of 6.5%. Can-Fite expects to release topline results for its Phase III trial in Q2 2022, with positive interim data supporting the development of its topical formulation as a complement to the oral treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
-
Rhea-AI Summary

Can-Fite BioPharma Ltd (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present at the 3rd Annual Dermatology Drug Development Summit on April 6, 2022, showcasing the lead drug candidate Piclidenoson for psoriasis treatment. Enrollment in the Phase III Comfort™ study is complete with 400 patients across 30 sites in Europe, Israel, and Canada, with topline data expected in Q2 2022. The company has received approximately $20 million from licensing agreements, enhancing its market reach in various countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
conferences
-
Rhea-AI Summary

Can-Fite BioPharma (NYSE: CANF) announced its financial results for the year ended December 31, 2021, reporting revenues of $0.85 million, up from $0.76 million in 2020. The company had a cash balance of $18.9 million at year-end. Key developments include a significant $42.7 million out-licensing deal with Ewopharma and positive Phase II results for Namodenoson in liver cancer. A Phase III study for liver cancer is set to start in H1 2022, and topline data for psoriasis is expected in Q2 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.75%
Tags
Rhea-AI Summary

Can-Fite BioPharma Ltd (NYSE: CANF) announced a Notice of Allowance from the U.S. Patent and Trademark Office for its method to treat advanced liver fibrosis with Namodenoson. This expansion targets various liver conditions including NASH and liver cancer, tapping into a market projected to exceed $20 billion by 2020.

The company is currently enrolling patients for a Phase IIb trial for NASH and plans to begin a Phase III trial for advanced liver cancer. Namodenoson boasts a strong safety profile and significant commercial potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.09%
Tags
none
-
Rhea-AI Summary

Can-Fite BioPharma Ltd (NYSE American: CANF) announced its CEO, Dr. Pnina Fishman, will present research at the CannX Medical Cannabis Conference on March 14-15, 2022, focusing on cannabinoids' role in liver cancer treatment.

Key findings indicate that CBD-rich T3/C15 can inhibit hepatocellular carcinoma growth at low concentrations by activating the A3 adenosine receptor. Can-Fite is exploring collaboration opportunities within the cannabis sector for potential licensing.

The abstract will be published in the Medical Cannabis and Cannabinoids journal.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.11%
Tags
none
-
Rhea-AI Summary

Can-Fite BioPharma (NYSE American: CANF) announced an unexpected delay in releasing top-line data from its Phase III Comfort™ study of Piclidenoson for treating plaque psoriasis, now expected in Q2 2022. The study involves over 400 patients across Europe, Israel, and Canada. Piclidenoson aims to target key cytokines involved in skin lesions. The psoriasis market is projected to reach $11.3 billion by 2025, with potential milestone payments from out-licensing agreements. The company remains optimistic about the drug's effectiveness with minimal side effects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.11%
Tags
none
Rhea-AI Summary

Can-Fite BioPharma (NYSE American: CANF) announced the enrollment of the first patient in a Phase IIb study for its drug candidate Namodenoson, targeting non-alcoholic steatohepatitis (NASH). This multicenter, randomized trial aims to assess Namodenoson's efficacy compared to placebo in 140 subjects over 36 weeks. The NASH market is projected to reach $35-$40 billion by 2025, highlighting the growth potential. Previous Phase IIa results indicated promising outcomes related to liver fibrosis and inflammation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
Can-Fite BioPharma Ltd.

NYSE:CANF

CANF Rankings

CANF Stock Data

12.42M
12.85M
1.51%
4.2%
Biotechnology
Healthcare
Link
Israel
Ramat Gan